134 related articles for article (PubMed ID: 33415720)
1. Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.
Farhadi J; Goshayeshi L; Motavalizadehkakhky A; Mehrzad J; Mehrad-Majd H
J Gastrointest Cancer; 2022 Mar; 53(1):179-186. PubMed ID: 33415720
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Tripartite Motif Containing 16 Expression in Patients with Gastric Cancer.
Afshar J; Mehrzad J; Mehrad-Majd H; Goshayeshi L; Saeidi J
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2445-2451. PubMed ID: 34452557
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.
Chao J; Zhang XF; Pan QZ; Zhao JJ; Jiang SS; Wang Y; Zhang JH; Xia JC
Med Oncol; 2014 Aug; 31(8):102. PubMed ID: 24994609
[TBL] [Abstract][Full Text] [Related]
4. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Fu H; Yang H; Zhang X; Wang B; Mao J; Li X; Wang M; Zhang B; Sun Z; Qian H; Xu W
J Exp Clin Cancer Res; 2018 Jul; 37(1):162. PubMed ID: 30031392
[TBL] [Abstract][Full Text] [Related]
5. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Song Y; Guo Q; Gao S; Hua K
Biochem Biophys Res Commun; 2018 Apr; 498(3):686-692. PubMed ID: 29524410
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.
Goshayeshi L; Afshar J; Mehrad-Majd H
Asian Pac J Cancer Prev; 2022 May; 23(5):1725-1731. PubMed ID: 35633558
[TBL] [Abstract][Full Text] [Related]
7. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
8. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Huang XQ; Zhang XF; Xia JH; Chao J; Pan QZ; Zhao JJ; Zhou ZQ; Chen CL; Tang Y; Weng DS; Zhang JH; Xia JC
Chin J Cancer; 2017 Sep; 36(1):77. PubMed ID: 28950898
[TBL] [Abstract][Full Text] [Related]
9. [Expression of hypoxia-inducible factor 1α in gastric cancer and its clinical signficance].
Wu YL; Hu LN; Zheng CD; Sun RC; Zhang SX; Yan Q; Li YX
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1418-23. PubMed ID: 27266349
[TBL] [Abstract][Full Text] [Related]
10. TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients.
Roshanazadeh MR; Adelipour M; Sanaei A; Chenane H; Rashidi M
BMC Res Notes; 2022 Sep; 15(1):312. PubMed ID: 36180926
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer.
Huang CY; Zhao JJ; Lv L; Chen YB; Li YF; Jiang SS; Wang W; Pan K; Zheng Y; Zhao BW; Wang DD; Chen YM; Yang L; Zhou ZW; Xia JC
PLoS One; 2013; 8(7):e69155. PubMed ID: 23935945
[TBL] [Abstract][Full Text] [Related]
12. Trim47 overexpression correlates with poor prognosis in gastric cancer.
Xia Y; Wei Z; Huang W; Wei X; He Y
Neoplasma; 2021 Mar; 68(2):307-316. PubMed ID: 33350849
[TBL] [Abstract][Full Text] [Related]
13. RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer.
Cheng Y; Yang B; Xi Y; Chen X
Tumour Biol; 2016 Nov; 37(11):14969-14978. PubMed ID: 27651161
[TBL] [Abstract][Full Text] [Related]
14. The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer.
Zhou Z; Xie J; Cai Y; Yang S; Chen Y; Wu H
Diagn Pathol; 2015 Jul; 10():128. PubMed ID: 26215716
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma.
Tang C; Gao X; Liu H; Jiang T; Zhai X
Int J Clin Exp Pathol; 2014; 7(8):4782-94. PubMed ID: 25197349
[TBL] [Abstract][Full Text] [Related]
16. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
17. eIF4EBP3 was downregulated by methylation and acted as a tumor suppressor by targeting eIF4E/β-catenin in gastric cancer.
Zhai S; Lin S; Lin Z; Xu J; Ji T; Chen K; Wu K; Liu H; Ying H; Fei W; Wang J; Fu G; Wang Y; Hu X; Cai X
Gastric Cancer; 2020 May; 23(3):483-496. PubMed ID: 31853750
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of TRIM29 expression in patients with gastric cancer.
Farhadi J; Mehrzad J; Mehrad-Majd H; Motavalizadehkakhky A
Gastroenterol Hepatol Bed Bench; 2022; 15(2):131-138. PubMed ID: 35845310
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognosis of MYOZ2 in gastric cancer.
Li YF; Zhu GY; Ma Y; Qu HY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5920-5927. PubMed ID: 30280773
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer.
Peng XC; Zeng Z; Huang YN; Deng YC; Fu GH
Cancer Med; 2018 Jun; 7(6):2592-2600. PubMed ID: 29665316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
